Starting February 2026, the Russian bioinformatics and medical AI solutions market enters a new era of regulation. A package of national standards has been approved: GOST R 71476-2024 'Artificial Intelligence. Concepts and Terminology' (an analogue of ISO 9001 for AI), GOST R 72484-2025 'Artificial Intelligence Systems in Healthcare. Terms and Definitions. Classification,' and GOST R 71671-2024 'Clinical Decision Support Systems Using Artificial Intelligence.' For researchers and startups, this means not just bureaucratic complexities, but a fundamental shift in development approaches. It is no longer enough to create a 'smart algorithm'—it is necessary to ensure decision-making transparency, process documentation, result reproducibility, and compliance with strict data quality requirements. This is precisely where ASI Biont AI agents become not just an automation tool, but a strategic solution for complying with the new standards. Our agents operate as autonomous research assistants that: 1. Maintain a complete protocol of all experiments and analyses—from raw data to final conclusions—meeting GOST requirements for AI process documentation. 2. Ensure result reproducibility through clear tracking of data versions, model parameters, and task execution conditions. 3. Automate routine biomedical data processing operations, freeing researchers for creative work. 4. Provide a transparent decision-making chain—every step of the agent can be tracked and explained, which is critically important for clinical decision support systems. While competitors spend months adapting their processes to new requirements, ASI Biont users are already operating in accordance with future standards. Our agents not only accelerate research—they create an infrastructure that inherently meets the regulatory expectations of 2026 and beyond. Key advantage: GOST compliance becomes not an additional burden, but a natural outcome of working with modern AI tools. Researchers receive not just automation, but a ready-made scientific process management system that already meets tomorrow's regulatory requirements today. This opens doors to collaboration with government institutions, major medical centers, and pharmaceutical companies, which from 2026 will require proof of compliance with national standards. ASI Biont becomes a bridge between innovative developments in bioinformatics and the regulated medical technology market.